Regencell Bioscience (NASDAQ:RGC) Stock Price Down 5.1% – What’s Next?

Regencell Bioscience Holdings Limited (NASDAQ:RGC) shares fell 5.1% on Tuesday . The stock traded as low as $24.30 and last traded at $24.48. 100,662 shares changed hands during trading, a decline of 67% from the average session volume of 305,052 shares. The stock had previously closed at $25.80.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Regencell Bioscience Trading Down 6.2%

The business’s 50-day simple moving average is $27.71 and its two-hundred day simple moving average is $24.81.

Regencell Bioscience (NASDAQ:RGC) last issued its earnings results on Friday, May 8th. The company reported $0.00 earnings per share for the quarter.

Hedge Funds Weigh In On Regencell Bioscience

A number of large investors have recently modified their holdings of the company. Bank of America Corp DE boosted its position in shares of Regencell Bioscience by 59,113.8% in the first quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after acquiring an additional 17,143 shares during the period. Amundi bought a new position in shares of Regencell Bioscience in the first quarter valued at approximately $219,000. Seven Fleet Capital Management LP bought a new position in shares of Regencell Bioscience in the fourth quarter valued at approximately $92,000. Vident Advisory LLC boosted its position in shares of Regencell Bioscience by 65.7% in the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after acquiring an additional 11,866 shares during the period. Finally, Hudson Bay Capital Management LP bought a new position in shares of Regencell Bioscience in the fourth quarter valued at approximately $275,000. 0.13% of the stock is currently owned by institutional investors.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.